Haemonetics

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Haemonetics reports robust Q1 earnings, eyes U.S. growth amid challenges

Haemonetics delivered strong financial performance in Q1 fiscal 2023, driven by robust revenue growth in both the Plasma and Hospital segments. The company's focus on the U.S. market and plans for accelerating growth indicate a positive outlook. However, challenges related to potential cuts in donor payments and varying market conditions outside the U.S. require careful navigation.

Haemonetics Corporation reports robust Q1 fiscal 2024 performance and eyes international expansion

Haemonetics Corporation delivered impressive Q1 fiscal 2024 results, driven by strong revenue growth and improved operating income. The company faces challenges in managing inventory replenishment and potential competition in the autoimmune space. However, opportunities lie in leveraging its robust product portfolio and expanding into international markets.

Haemonetics reports strong Q3 performance, eyes European expansion for growth

Haemonetics delivered robust financial results in Q3, driven by strong revenue growth and strategic initiatives. While facing challenges related to staffing and donor issues, the company is well-positioned to leverage opportunities in expanding markets and technological advancements to drive future growth.

Haemonetics posts robust earnings, eyes global expansion for growth

Haemonetics delivered strong financial results in Q4 2023 and fiscal '23, driven by robust revenue growth and improved earnings per share.
The company's focus on key segments like Plasma, Hospital, Hemostasis, and Vascular Closure positions it well for future growth and market expansion.
While facing challenges such as cost pressures and competitive landscapes, Haemonetics remains optimistic about its ability to drive profitability and market share.
Strategic initiatives, including a modest ramp in market resources and international expansion, present opportunities for Haemonetics to capitalize on market demand and enhance shareholder value.

Haemonetics excels in Q1 '24, eyes growth amid challenges

Haemonetics delivered robust financial performance in Q1 '24, with significant revenue growth and margin expansion.
While facing challenges like product recalls, the company remains focused on value creation and growth acceleration strategies.
Opportunities for growth exist through market scaling, product innovations, and leveraging trial implications for demand growth.

Haemonetics posts robust Q2 earnings, eyes U.S. and international growth

Haemonetics reported strong Q2 results with increased earnings and revenue growth. The company's strategic acquisitions and focus on innovation position it well for future expansion. Challenges in the Blood Center segment require attention, but overall, Haemonetics is poised for continued growth.

Haemonetics posts robust Q3 earnings, eyes growth through innovation

Haemonetics delivered strong financial performance in Q3 2024, driven by revenue growth and operational efficiency improvements.
The company's focus on innovation, technology enhancements, and strategic acquisitions positions it well for future growth and market leadership.
While facing challenges in certain revenue segments, Haemonetics remains poised to capitalize on opportunities for expansion and margin improvement.

Haemonetics posts robust Q4 results, eyes growth through acquisitions

Haemonetics' Q4 2024 performance reflects strong revenue growth and profitability, driven by successful product launches and acquisitions.
While the company faces challenges in margin targets and integration post-acquisitions, strategic focus on innovation and market expansion presents growth opportunities.
Emphasis on non-GAAP measures and regulatory clearances underscores Haemonetics' commitment to transparency and product quality.
Fiscal year 2025 guidance signals a positive outlook for revenue growth and operational efficiency, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Investors don't seem to be buying the company's rosy 2022 guidance.

Why Haemonetics Stock Fell 13% Today

Haemonetics Corporation (HAE) CEO Chris Simon on Q4 2021 Results - Earnings Call Transcript

Haemonetics (HAE) delivered earnings and revenue surprises of -31.34% and -0.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Q4 Earnings and Revenues Miss Estimates

Shares of Haemonetics (NYSE:HAE) rose 2.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 33.33% over the past year to $0.46, which missed the estimate of $0.67.

Recap: Haemonetics Q4 Earnings

BOSTON, May 13, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2021, which ended April 3, 2021, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

Haemonetics 4th Quarter Fiscal Year 2021 Earnings Release Available on Investor Relations Website

Continued benefits from the NexSys device and NexLynk DMS along with robust TEG devices sales are expected to have contributed to Haemonetics (HAE) fourth-quarter top line.

Haemonetics (HAE) to Report Q4 Earnings: What's in the Cards?

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for

BOSTON, April 29, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced that the full peer-reviewed results of the IMproving PlasmA CollecTion (IMPACT) trial have been published in TRANSFUSION, the prime journal for transfusion medicine related research. The publication expands upon the IMPACT trial data presented in October 2020 in a plenary session at the AABB conference.

Peer-Reviewed Results of Haemonetics' Improving Plasma Collection (IMPACT) Trial Published in the Journal TRANSFUSION

BOSTON, April 23, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2021 financial results at 6:00 am EDT on Thursday, May 13, 2021. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on May 13, 2021.

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2021 Results: May 13, 2021

The stock price of Haemonetics, best known for its blood and plasma supplies and services, plunged over 36% in a single trading session yesterday. This can be attributed to one of its large customers - CSL Pharma - stating that it will not renew its contract (expires in June 2022) with Haemonetics.

What's Next For Haemonetics Stock?

BOSTON, April 19, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics" or the "Company"), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that CSL Plasma, Ltd. ("CSL") has informed Haemonetics of its intent not to renew its Supply Agreement with Haemonetics for the use of PCS2® Plasma Collection System devices and the purchase of disposable plasmapheresis kits in the U.S. following the expiration of the current term in June 2022.

Haemonetics Provides Update On U.S. Plasma Business

Haemonetics stock, best known for its blood and plasma supplies and services, has fallen by 3.5% in the last week, while it is down 7% over the last ten days. HAE stock has been on a decline since it reported its fiscal Q3 2021 results in early February, 2021.

Will Haemonetics Stock Rebound After The Recent Drop?

Investor are optimistic about Haemonetics (HAE) on its continued Plasma franchise growth and huge potential of Hemostasis Management franchise.

Here's Why You Should Add Haemonetics (HAE) to Your Portfolio

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

Haemonetics (HAE) Down 5.8% Since Last Earnings Report: Can It Rebound?

BOSTON, March 2, 2021 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2026 (the "notes") in a private offering (the "offering") to qualified...

Haemonetics Prices $435.0 Million Convertible Senior Notes Offering

BOSTON, Feb. 26, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the Jefferies Plasma Summit on Thursday, March 11, 2021, at 10:45 a.m. ET. The public may access Mr. Simon's video presentation live via webcast at:...

Haemonetics To Present At The Jefferies Plasma Summit

Haemonetics has been a pure play on blood, or better said, hematology. The company has seen modest sales gains in recent years yet has delivered on real margin improvements.

Haemonetics: Pure Play On Hematology

Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.

Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts

Haemonetics Corporation (HAE) CEO Christopher Simon on Q3 2021 Results - Earnings Call Transcript

Shares of Haemonetics (NYSE:HAE) were flat in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 13.83% year over year to $0.81, which beat the estimate of $0.65.

Recap: Haemonetics Q3 Earnings

BOSTON, Feb. 2, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal 2021, which ended December 26, 2020, are available on its Investor Relations website. The Company will host a conference call and webcast with investors...

Haemonetics 3rd Quarter Fiscal Year 2021 Earnings Release Available on Investor Relations Website

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Haemonetics (HAE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

BOSTON, Jan. 22, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics"), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, affirms its support of new guidance issued by the U.S. Food and Drug...

Haemonetics Welcomes New FDA Guidance on Viscoelastic Testing During COVID-19 Pandemic

BOSTON, Jan. 20, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics"), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to acquire...

Haemonetics To Acquire Cardiva Medical, Inc. To Expand Hospital Portfolio

Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.

News for Haemonetics Stock (HAE)